Agravamiento de la depresión sintomática en pacientes con enfermedad de Parkinson en la pandemia de COVID-19: una revisión sistemática
##plugins.themes.bootstrap3.article.sidebar##
Publicado
Dec 28, 2022
##plugins.themes.bootstrap3.article.main##
Resumen
Objetivo: Investigar en la literatura si había un aumento de la depresión en pacientes con la enfermedad de Parkinson en la pandemia de COVID-19. Métodos: La revisión sistemática se realizó según el protocolo de Revisiones Sistemáticas y Meta-Análisis (PRISMA), quedando registrada en PROSPERO con el número CRD 42021289109. La búsqueda de artículos se realizó en agosto de 2021, utilizando los descriptores "Parkinson's Disease", "COVID-19" y "Depression", combinados con el operador AND, en las bases de datos: PubMed, PsycInfo y Virtual Health Library (BVS). Se identificaron 67 registros y se evaluaron 29 artículos, de los cuales 10 se incluyeron en esta revisión. Resultados: La mayoría de los estudios informaron de una diferencia significativa en las puntuaciones de depresión, lo que sugiere que en el periodo de la pandemia los pacientes experimentaron un empeoramiento de este síntoma no motor. Los resultados señalan que la falta de apoyo familiar, la reducción de la actividad física y el estrés relacionado con la COVID-19 son algunos de los factores que influyeron en el empeoramiento de la depresión. Observaciones Finales: Los límites impuestos por la pandemia y el aislamiento social provocaron, aunque de forma reducida, el agravamiento de la depresión en la población estudiada.
##plugins.themes.bootstrap3.article.details##
Cómo citar
VenturaS. de A., MirandaI. P., & SantosR. M. S. (2022). Agravamiento de la depresión sintomática en pacientes con enfermedad de Parkinson en la pandemia de COVID-19: una revisión sistemática. Revista Eletrônica Acervo Saúde, 15(12), e11340. https://doi.org/10.25248/reas.e11340.2022
Número
Sección
Revisão Bibliográfica
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Citas
1. ASSOGNA F, et al. Drug Choices and Advancements for Managing Depression in Parkinson’s Disease. Current Neuropharmacology, 2020; 18(4): 277–287.
2. BALCI B, et al. Impact of the COVID-19 pandemic on physical activity, anxiety, and depression in patients with Parkinson’s disease. International Journal of Rehabilitation Research, 2021; 44(0342): 173–176.
3. BEZERRA KP, et al. Ensino remoto em universidades públicas estaduais: O futuro que se faz presente. Research, Society and Development, 2020; 9(9): 1–17.
4. CABREIRA V e MASSANO J. Doença de Parkinson: Revisão Clínica e Atualização. Acta Médica Portuguesa, 2019; 32(10): 661–670.
5. CHAKRABORTY I e MAITY P. COVID-19 outbreak: Migration, effects on society, global environment and prevention. Science of the Total Environment, 2020; 728: 1–7.
6. DE RUS JACQUET A, et al. Clinical perception and management of Parkinson’s disease during the COVID-19 pandemic: A Canadian experience. Parkinsonism and Related Disorders, 2021;91: 66–76.
7. DITZEN B e HEINRICHS M. Psychobiology of social support: The social dimension of stress buffering. Restorative Neurology and Neuroscience, 2014; 32: 149–162.
8. DOMINGOS J, et al. Is Being Physically Active Enough or Do People with Parkinson’s Disease Need Structured Supervised Exercise? Lessons Learned from COVID-19. International Journal of Environmental Research and Public Health, 2022; 19(4): 1–12.
9. DOMMERSHUIJSEN LJ, et al. Mental health in people with Parkinson’s disease during the COVID-19 pandemic: potential for targeted interventions? NPJ Parkinson's disease, 2021; 7(1): 1-9.
10. DORSEY ER e BLOEM BR. The Parkinson pandemic - A call to action. JAMA Neurology, 2018; 75(1): 9–10.
11. DRAGAŠEVIĆ-MIŠKOVIĆ NT, et al. Impact of depression on gait variability in Parkinson's disease. Clin Neurol Neurosurg, 2021; 200(106324).
12. EL OTMANI H, et al. No impact of confinement during COVID-19 pandemic on anxiety and depression in Parkinsonian patients. Revue Neurologique, 2021; 177(3): 272–274.
13. FALLA M, et al. Lockdown effects on Parkinson’s disease during COVID-19 pandemic: a pilot study. Acta neurologica Belgica, 2021; 121(5): 1191–1198.
14. GAZEWOODJD, et al. Parkinson disease: An update. American Family Physician, 2013;87(4): 267–273.
15. HAAS AN, et al. Association between mental health and physical activity levels in people with Parkinson’s disease during the COVID-19 pandemic: an observational cross-sectional survey in Brazil. Sport Sciences for Health, 2022; 1–7.
16. HELMY A, et al. Baseline predictors of progression of Parkinson’s disease in a sample of Egyptian patients: clinical and biochemical. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2022; 58(9): 1–10.
17. HIGGINS JPT, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Online), 2011; 343(7829): 1–9.
18. HUANG T-T, et al. Physical fitness exercise versus cognitive behavior therapy on reducing the depressive symptoms among community-dwelling elderly adults: A randomized controlled trial. International journal of nursing studies. Int J Nurs Stud, 2015; (52): 1542–52.
19. JANIRI D, et al. COVID-19 Pandemic and Psychiatric Symptoms: The Impact on Parkinson’s Disease in the Elderly. Frontiers in Psychiatry, 2020; 11: 1–8.
20. KETIGIAN L, et al. Transition and Sustainability of an Online Care Model for People with Parkinson's Disease in Response to the COVID-19 Pandemic. Frontiers in public health, 2022; 9(772805): 1-10.
21. KITANI-MORII F, et al. Risk factors for neuropsychiatric symptoms in patients with Parkinson’s disease during COVID-19 pandemic in Japan. PLoS ONE, 2021; 16(1): 1–13.
22. KNAPIK A, et al. Isolation Related to the COVID-19 Pandemic in People Suffering from Parkinson’s Disease and Activity, Self-Assessment of Physical Fitness and the Level of Affective Disorders. Healthcare, 2021; 9(11): 1-8.
23. KWOK JYY, et al. Stay mindfully active during the coronavirus pandemic: a feasibility study of mHealth-delivered mindfulness yoga program for people with Parkinson’s disease. BMC Complementary Medicine and Therapies, 2022; 22(37): 1–12.
24. MONTANARO E, et al. Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic. Neurological Sciences, 2021; 43(1): 341–348.
25. PFEIFFER RF. Non-motor symptoms in Parkinson’s disease. Parkinsonism and Related Disorders, 2015; 22: 1–4.
26. PONTONE GM, MILLS KA. Optimal Treatment of Depression and Anxiety in Parkinson's Disease. The American journal of geriatric psychiatry, 2021; 29(6): 530–540.
27. RASS V, et al. Factors associated with impaired quality of life three months after being diagnosed with COVID-19. Quality of Life Research, 2021; 31: 1401–1414.
28. RIZEK P, et al. An update on the diagnosis and treatment of Parkinson disease. CMAJ, 2016; 188(16): 1157–1165.
29. SAVICA R, et al. When do a-Synucleinopathies start? An epidemiological timeline a review. JAMA Neurology, 2018; 75(4): 503–509.
30. SHALASH A, et al. Mental Health, Physical Activity, and Quality of Life in Parkinson’s Disease During COVID-19 Pandemic. Movement Disorders, 2020; 35(7): 1097–1099.
31. SHAMSEER L, et al. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. BMJ (Online), 2015; 349: 1–25.
32. SUBRAMANIAN I, et al. Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life. npj Parkinson’s Disease, 2020; 6(28): 1–8.
33. SUZUKI K, et al. Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Parkinson’s Disease and Their Caregivers: A Single-Center Survey in Tochigi Prefecture. Journal of Parkinson’s Disease, 2021; 11(3): 1047–1056.
34. VAN DER HEIDE A, et al. The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson’s Disease. Journal of Parkinson’s Disease, 2020; 10(4): 1355–1364.
35. VENKATESH AES e EDIRAPPULI S. Social distancing in covid-19: what are the mental health implications? BMJ (Clinical research ed.), 2020; 368(1089): 1.
36. VOON V, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. The Lancet. Neurology, 2017; 16(3): 238–250.
37. WALTON L, et al. Digital Dance for People with Parkinson's Disease During the COVID-19 Pandemic: A Feasibility Study. Frontiers in neurology, 2022; 12(743432).
38. WANG Z, et al. Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA neurology, 2020; 78(1): 1–11.
39. WORLD HEALTH ORGANIZATION. Depression and Other Common Mental Disorders: Global Health Estimates. 2017. Disponível em: https://apps.who.int/iris/handle/10665/254610. Acessado em: 12 de fevereiro de 2021.
40. WU PL, et al. Effectiveness of physical activity on patients with depression and Parkinson’s disease: A systematic review. PLoS ONE, 2017; 12(7): 1–14.
41. XIA Y, et al. Investigation on sleep and mental health of patients with Parkinson’s disease during the Coronavirus disease 2019 pandemic. Sleep Medicine, 2020; 75: 428–433.
42. XU Y, et al. COVID-19 manifestations in people with Parkinson’s disease: a USA cohort. Journal of Neurology, 2022; 269(3): 1107–1113.
2. BALCI B, et al. Impact of the COVID-19 pandemic on physical activity, anxiety, and depression in patients with Parkinson’s disease. International Journal of Rehabilitation Research, 2021; 44(0342): 173–176.
3. BEZERRA KP, et al. Ensino remoto em universidades públicas estaduais: O futuro que se faz presente. Research, Society and Development, 2020; 9(9): 1–17.
4. CABREIRA V e MASSANO J. Doença de Parkinson: Revisão Clínica e Atualização. Acta Médica Portuguesa, 2019; 32(10): 661–670.
5. CHAKRABORTY I e MAITY P. COVID-19 outbreak: Migration, effects on society, global environment and prevention. Science of the Total Environment, 2020; 728: 1–7.
6. DE RUS JACQUET A, et al. Clinical perception and management of Parkinson’s disease during the COVID-19 pandemic: A Canadian experience. Parkinsonism and Related Disorders, 2021;91: 66–76.
7. DITZEN B e HEINRICHS M. Psychobiology of social support: The social dimension of stress buffering. Restorative Neurology and Neuroscience, 2014; 32: 149–162.
8. DOMINGOS J, et al. Is Being Physically Active Enough or Do People with Parkinson’s Disease Need Structured Supervised Exercise? Lessons Learned from COVID-19. International Journal of Environmental Research and Public Health, 2022; 19(4): 1–12.
9. DOMMERSHUIJSEN LJ, et al. Mental health in people with Parkinson’s disease during the COVID-19 pandemic: potential for targeted interventions? NPJ Parkinson's disease, 2021; 7(1): 1-9.
10. DORSEY ER e BLOEM BR. The Parkinson pandemic - A call to action. JAMA Neurology, 2018; 75(1): 9–10.
11. DRAGAŠEVIĆ-MIŠKOVIĆ NT, et al. Impact of depression on gait variability in Parkinson's disease. Clin Neurol Neurosurg, 2021; 200(106324).
12. EL OTMANI H, et al. No impact of confinement during COVID-19 pandemic on anxiety and depression in Parkinsonian patients. Revue Neurologique, 2021; 177(3): 272–274.
13. FALLA M, et al. Lockdown effects on Parkinson’s disease during COVID-19 pandemic: a pilot study. Acta neurologica Belgica, 2021; 121(5): 1191–1198.
14. GAZEWOODJD, et al. Parkinson disease: An update. American Family Physician, 2013;87(4): 267–273.
15. HAAS AN, et al. Association between mental health and physical activity levels in people with Parkinson’s disease during the COVID-19 pandemic: an observational cross-sectional survey in Brazil. Sport Sciences for Health, 2022; 1–7.
16. HELMY A, et al. Baseline predictors of progression of Parkinson’s disease in a sample of Egyptian patients: clinical and biochemical. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2022; 58(9): 1–10.
17. HIGGINS JPT, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Online), 2011; 343(7829): 1–9.
18. HUANG T-T, et al. Physical fitness exercise versus cognitive behavior therapy on reducing the depressive symptoms among community-dwelling elderly adults: A randomized controlled trial. International journal of nursing studies. Int J Nurs Stud, 2015; (52): 1542–52.
19. JANIRI D, et al. COVID-19 Pandemic and Psychiatric Symptoms: The Impact on Parkinson’s Disease in the Elderly. Frontiers in Psychiatry, 2020; 11: 1–8.
20. KETIGIAN L, et al. Transition and Sustainability of an Online Care Model for People with Parkinson's Disease in Response to the COVID-19 Pandemic. Frontiers in public health, 2022; 9(772805): 1-10.
21. KITANI-MORII F, et al. Risk factors for neuropsychiatric symptoms in patients with Parkinson’s disease during COVID-19 pandemic in Japan. PLoS ONE, 2021; 16(1): 1–13.
22. KNAPIK A, et al. Isolation Related to the COVID-19 Pandemic in People Suffering from Parkinson’s Disease and Activity, Self-Assessment of Physical Fitness and the Level of Affective Disorders. Healthcare, 2021; 9(11): 1-8.
23. KWOK JYY, et al. Stay mindfully active during the coronavirus pandemic: a feasibility study of mHealth-delivered mindfulness yoga program for people with Parkinson’s disease. BMC Complementary Medicine and Therapies, 2022; 22(37): 1–12.
24. MONTANARO E, et al. Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic. Neurological Sciences, 2021; 43(1): 341–348.
25. PFEIFFER RF. Non-motor symptoms in Parkinson’s disease. Parkinsonism and Related Disorders, 2015; 22: 1–4.
26. PONTONE GM, MILLS KA. Optimal Treatment of Depression and Anxiety in Parkinson's Disease. The American journal of geriatric psychiatry, 2021; 29(6): 530–540.
27. RASS V, et al. Factors associated with impaired quality of life three months after being diagnosed with COVID-19. Quality of Life Research, 2021; 31: 1401–1414.
28. RIZEK P, et al. An update on the diagnosis and treatment of Parkinson disease. CMAJ, 2016; 188(16): 1157–1165.
29. SAVICA R, et al. When do a-Synucleinopathies start? An epidemiological timeline a review. JAMA Neurology, 2018; 75(4): 503–509.
30. SHALASH A, et al. Mental Health, Physical Activity, and Quality of Life in Parkinson’s Disease During COVID-19 Pandemic. Movement Disorders, 2020; 35(7): 1097–1099.
31. SHAMSEER L, et al. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. BMJ (Online), 2015; 349: 1–25.
32. SUBRAMANIAN I, et al. Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life. npj Parkinson’s Disease, 2020; 6(28): 1–8.
33. SUZUKI K, et al. Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Parkinson’s Disease and Their Caregivers: A Single-Center Survey in Tochigi Prefecture. Journal of Parkinson’s Disease, 2021; 11(3): 1047–1056.
34. VAN DER HEIDE A, et al. The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson’s Disease. Journal of Parkinson’s Disease, 2020; 10(4): 1355–1364.
35. VENKATESH AES e EDIRAPPULI S. Social distancing in covid-19: what are the mental health implications? BMJ (Clinical research ed.), 2020; 368(1089): 1.
36. VOON V, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. The Lancet. Neurology, 2017; 16(3): 238–250.
37. WALTON L, et al. Digital Dance for People with Parkinson's Disease During the COVID-19 Pandemic: A Feasibility Study. Frontiers in neurology, 2022; 12(743432).
38. WANG Z, et al. Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA neurology, 2020; 78(1): 1–11.
39. WORLD HEALTH ORGANIZATION. Depression and Other Common Mental Disorders: Global Health Estimates. 2017. Disponível em: https://apps.who.int/iris/handle/10665/254610. Acessado em: 12 de fevereiro de 2021.
40. WU PL, et al. Effectiveness of physical activity on patients with depression and Parkinson’s disease: A systematic review. PLoS ONE, 2017; 12(7): 1–14.
41. XIA Y, et al. Investigation on sleep and mental health of patients with Parkinson’s disease during the Coronavirus disease 2019 pandemic. Sleep Medicine, 2020; 75: 428–433.
42. XU Y, et al. COVID-19 manifestations in people with Parkinson’s disease: a USA cohort. Journal of Neurology, 2022; 269(3): 1107–1113.